SEC Form 4 · accession 0001437749-17-005086
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth M Keiley
Officer — Senior VP & General Counsel
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Mar 20, 2017 | M | 3,000 | $0.81 | A | 25,429 | D | |
| Ordinary Shares | Mar 20, 2017 | S | 3,000 | $16.05 | D | 22,429 | D | |
| Ordinary Shares | Mar 20, 2017 | M | 8,185 | $0.81 | A | 30,614 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F2 | $0.81 | Mar 20, 2017 | M | 3,000 | D | — | Sep 30, 2022 | Ordinary Shares | 3,000 | 8,185 | D |
| Share Option (Right to Buy)F2 | $0.81 | Mar 20, 2017 | M | 8,185 | D | — | Sep 30, 2022 | Ordinary Shares | 8,185 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 8 2016.
- F2Exercise from an option granted October 29, 2012, which became fully vested on September 30, 2016.